Billions of dollars are spent every year to help patients with type 2 diabetes manage their insulin and control their blood sugar, but Fractyl Laboratories Inc. is trying to address the root cause of insulin resistance with its Revita duodenal mucosal resurfacing (DMR) system.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?